{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:50:35Z","timestamp":1790700635454,"version":"4.1.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T00:00:00Z","timestamp":1598572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["CARAT [667980]"],"award-info":[{"award-number":["CARAT [667980]"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.02028","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T04:45:43Z","timestamp":1598589943000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":68,"title":["Highly Efficient Generation of Transgenically Augmented CAR NK Cells Overexpressing CXCR4"],"prefix":"10.3389","volume":"11","author":[{"given":"Arezoo","family":"Jamali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamshid","family":"Hadjati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Madjd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid Reza","family":"Mirzaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic B.","family":"Thalheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwani","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halvard","family":"Bonig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Ullrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,8,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts.","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Mol Med."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00631","article-title":"The rise of allogeneic natural killer cells as a platform for cancer immunotherapy: recent innovations and future developments.","volume":"8","author":"Veluchamy","year":"2017","journal-title":"Front Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1089\/hum.2012.080","article-title":"Inhibition of intracellular antiviral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy.","volume":"23","author":"Sutlu","year":"2012","journal-title":"Hum Gene Ther."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/4054815","article-title":"Viral and nonviral engineering of natural killer cells as emerging adoptive cancer immunotherapies.","volume":"2018","author":"Matosevic","year":"2018","journal-title":"J Immunol Res."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02873","article-title":"Efficient and robust NK-cell transduction with baboon envelope pseudotyped lentivector.","volume":"10","author":"Colamartino","year":"2019","journal-title":"Front Immunol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03123","article-title":"High cytotoxic efficiency of lentivirally and alpharetrovirally engineered CD19-specific chimeric antigen receptor natural killer cells against acute lymphoblastic leukemia.","volume":"10","author":"M\u00fcller","year":"2019","journal-title":"Front Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000495771","article-title":"CAR-expressing natural killer cells for cancer retargeting.","volume":"46","author":"Kloess","year":"2019","journal-title":"Transfus Med Hemother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1016\/j.ymthe.2017.06.012","article-title":"Engineering natural killer cells for cancer immunotherapy.","volume":"25","author":"Rezvani","year":"2017","journal-title":"Mol Ther Nucleic Acids."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00283","article-title":"Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer.","volume":"9","author":"Mehta","year":"2018","journal-title":"Front Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1038\/leu.2017.57","article-title":"Fully human CD19-specific chimeric antigen receptors for T-cell therapy.","volume":"31","author":"Sommermeyer","year":"2017","journal-title":"Leukemia."},{"key":"B11","doi-asserted-by":"publisher","first-page":"9207","DOI":"10.1002\/jcp.27599","article-title":"Construction and functional characterization of a fully human anti-CD19 chimeric antigen receptor (huCAR)-expressing primary human T cells.","volume":"234","author":"Mirzaei","year":"2019","journal-title":"J Cell Physiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"264","DOI":"10.18502\/ijaai.v19i3.3454","article-title":"Construction and functional characterization of a fully human anti-mesothelin chimeric antigen receptor (CAR) expressing T cell.","volume":"19","author":"Jafarzadeh","year":"2020","journal-title":"Iran J Allergy Asthma Immunol."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-020-01546-6","article-title":"Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells.","volume":"39","author":"Masoumi","year":"2020","journal-title":"J Exp Clin Cancer Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"5776","DOI":"10.1111\/jcmm.13867","article-title":"Disseminated tumour cells in bone marrow are the source of cancer relapse after therapy.","volume":"22","author":"Sai","year":"2018","journal-title":"J Cell Mol Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ccell.2017.08.001","article-title":"Increased vascular permeability in the bone marrow microenvironment contributes to disease progression and drug response in acute myeloid leukemia.","volume":"32","author":"Passaro","year":"2017","journal-title":"Cancer Cell."},{"key":"B16","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.exphem.2014.08.003","article-title":"Activation of the vascular niche supports leukemic progression and resistance to chemotherapy.","volume":"42","author":"Poulos","year":"2014","journal-title":"Exp. Hematol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3626","DOI":"10.1182\/blood-2007-08-106203","article-title":"CCL3 and CXCL12 regulate trafficking of mouse bone marrow NK cell subsets.","volume":"111","author":"Bernardini","year":"2008","journal-title":"Blood."},{"key":"B18","doi-asserted-by":"publisher","first-page":"4863","DOI":"10.1182\/blood-2011-06-362574","article-title":"Sequential desensitization of CXCR4 and S1P5 controls natural killer cell trafficking.","volume":"118","author":"Mayol","year":"2011","journal-title":"Blood."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01262","article-title":"Enhanced bone marrow homing of natural killer cells following mRNA transfection with gain-of-function variant CXCR4R334X.","volume":"10","author":"Levy","year":"2019","journal-title":"Front Immunol."},{"key":"B20","first-page":"406","article-title":"Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia.","volume":"24","author":"Robertson","year":"1996","journal-title":"Exp. Hematol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/gt.2010.62","article-title":"Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector.","volume":"17","author":"Becker","year":"2010","journal-title":"Gene Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"9854","DOI":"10.1128\/JVI.00357-09","article-title":"Development of a human immunodeficiency virus type 1-based lentiviral vector that allows efficient transduction of both human and rhesus blood cells.","volume":"83","author":"Uchida","year":"2009","journal-title":"J Virol."},{"key":"B23","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","article-title":"A third-generation lentivirus vector with a conditional packaging system.","volume":"72","author":"Dull","year":"1998","journal-title":"J Virol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1038\/mt.2016.70","article-title":"Development of third-generation cocal envelope producer cell lines for robust lentiviral gene transfer into hematopoietic stem cells and T-cells.","volume":"24","author":"Humbert","year":"2016","journal-title":"Mol Ther Nucleic Acids."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.4049\/jimmunol.1500956","article-title":"Exclusive transduction of human CD4+ T cells upon systemic delivery of CD4-targeted lentiviral vectors.","volume":"195","author":"Zhou","year":"2015","journal-title":"J. Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.omtm.2019.03.003","article-title":"Highly efficient and selective CAR-gene transfer using CD4- and CD8-targeted lentiviral vectors.","volume":"13","author":"Jamali","year":"2019","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3324\/haematol.2015.140368","article-title":"Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey.","volume":"101","author":"Ku\u00e7i","year":"2016","journal-title":"Haematologica."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00266","article-title":"Genetic manipulation of NK cells for cancer immunotherapy: techniques and clinical implications.","volume":"6","author":"Carlsten","year":"2015","journal-title":"Front Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.coi.2018.03.013","article-title":"Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering.","volume":"51","author":"Daher","year":"2018","journal-title":"Curr. Opin. Immunol."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02683","article-title":"CAR-engineered NK cells for the treatment of glioblastoma: turning innate effectors into precision tools for cancer immunotherapy.","volume":"10","author":"Burger","year":"2019","journal-title":"Front Immunol."},{"key":"B31","first-page":"1083","article-title":"First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.","volume":"8","author":"Tang","year":"2018","journal-title":"Am J Cancer Res."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/srep11483","article-title":"CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells.","volume":"5","author":"Han","year":"2015","journal-title":"Sci Rep."},{"key":"B33","doi-asserted-by":"publisher","first-page":"958","DOI":"10.3109\/10428194.2011.634048","article-title":"Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens.","volume":"53","author":"Boissel","year":"2012","journal-title":"Leuk Lymphoma."},{"key":"B34","doi-asserted-by":"publisher","first-page":"17481","DOI":"10.1073\/pnas.0804788105","article-title":"Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas.","volume":"105","author":"Kruschinski","year":"2008","journal-title":"Proc Natl Acad Sci USA."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.4161\/onci.28147","article-title":"Are natural killer cells superior CAR drivers?","volume":"3","author":"Klingemann","year":"2014","journal-title":"Oncoimmunology."},{"key":"B36","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/CJI.0b013e3181bb46f7","article-title":"IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in vivo influence after haploidentical NK cell infusion.","volume":"33","author":"Huenecke","year":"2010","journal-title":"J Immunother."},{"key":"B37","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/mt.2014.219","article-title":"Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2\/HER2-specific chimeric antigen receptor.","volume":"23","author":"Sch\u00f6nfeld","year":"2015","journal-title":"Mol Ther Nucleic Acids."},{"key":"B38","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jcyt.2016.10.009","article-title":"Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.","volume":"19","author":"Oelsner","year":"2017","journal-title":"Cytotherapy."},{"key":"B39","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1182\/blood-2004-12-4797","article-title":"Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells.","volume":"106","author":"Imai","year":"2005","journal-title":"Blood."},{"key":"B40","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors.","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0275-9","article-title":"Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma.","volume":"5","author":"Kremer","year":"2017","journal-title":"J Immunother Cancer."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00957","article-title":"Human CAR NK cells: a new non-viral method allowing high efficient transfection and strong tumor cell killing.","volume":"10","author":"Ingegnere","year":"2019","journal-title":"Front Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/CJI.0000000000000082","article-title":"Engineering NK cells modified with an EGFRvIII-specific chimeric antigen receptor to overexpress CXCR4 improves immunotherapy of CXCL12\/SDF-1\u03b1-secreting Glioblastoma.","volume":"38","author":"M\u00fcller","year":"2015","journal-title":"J Immunother."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1172\/JCI97454","article-title":"Redirection to the bone marrow improves T cell persistence and antitumor functions.","volume":"128","author":"Khan","year":"2018","journal-title":"J Clin Invest."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00402","article-title":"Dysregulation of chemokine\/chemokine receptor axes and NK cell tissue localization during diseases.","volume":"7","author":"Bernardini","year":"2016","journal-title":"Front Immunol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.02028\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T04:45:46Z","timestamp":1598589946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.02028\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,28]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2020.02028"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.02028","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,28]]},"article-number":"2028"}}